{"id":3035,"date":"2022-01-31T17:04:28","date_gmt":"2022-01-31T07:04:28","guid":{"rendered":"https:\/\/orthocell.com\/us\/?p=3035"},"modified":"2022-02-01T14:12:05","modified_gmt":"2022-02-01T04:12:05","slug":"quarterly-report-period-to-december-2021","status":"publish","type":"post","link":"\/americas\/quarterly-report-period-to-december-2021\/","title":{"rendered":"Quarterly Report &#8211; Period To December 2021"},"content":{"rendered":"<p><a href=\"https:\/\/www.orthocell.com\/us.au\/\">Orthocell<\/a> (ASX $OCC) <span style=\"font-weight: 400;\">has today published its Quarterly Report for the period ended 31 December 2021.<\/span><\/p>\n<p><b>Primary achievements include:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Phase 2a clinical study results show that OrthoATI\u2122 is significantly more effective than steroid injection for treatment of rotator cuff tendon tears.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">OrthoATI\u2122US commercialisation plans accelerated with FDA engagement and commercial preparation to support a randomised controlled study.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Significant progress towards engaging a US market distribution partner for Striate+ dental membrane, together with promising use and feedback from key opinion leaders.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Discussions and tangible progress with the Australian TGA regarding our application for approval to supply Remplir\u2122 in the Australian market for peripheral nerve repair.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Focused discussions with US FDA regarding the US regulatory pathway for Remplir\u2122, with data to support expedited review and reimbursement positioning.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">We have a strong balance sheet, with a closing cash balance of A$13.6m at the end of the Quarter &#8211; sufficient funds to support key regulatory approvals and our commercialisation goals.<\/span><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC_4C\"><b>Click here to read today\u2019s ASX release.\u00a0<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021.<\/p>\n","protected":false},"author":2,"featured_media":3036,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3035","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/americas\/wp-json\/wp\/v2\/posts\/3035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/americas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/americas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/comments?post=3035"}],"version-history":[{"count":1,"href":"\/americas\/wp-json\/wp\/v2\/posts\/3035\/revisions"}],"predecessor-version":[{"id":3037,"href":"\/americas\/wp-json\/wp\/v2\/posts\/3035\/revisions\/3037"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/media\/3036"}],"wp:attachment":[{"href":"\/americas\/wp-json\/wp\/v2\/media?parent=3035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/categories?post=3035"},{"taxonomy":"post_tag","embeddable":true,"href":"\/americas\/wp-json\/wp\/v2\/tags?post=3035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}